S1 Biopharma, which is developing a combined therapy of existing drugs for female sexual dysfunction, lowered the proposed deal size for its upcoming IPO on Wednesday. The New York, NY-based company now plans to raise $23 million by offering 1.8 million units, which include one common share as well as one Series A and one Series B warrant, at a price range of $12 to $14. The company had previously filed to offer 2.8 million common shares at a range of $12 to $14. At the midpoint of the revised range, S1 Biopharma will raise -36% fewer proceeds than previously anticipated and now commands a ...more
Vyrix Pharmaceuticals, a biotech developing an oral treatment for premature ejaculation, withdrew its plans for an initial public offering on Monday citing market conditions. The company originally filed for a $30 million IPO in April 2014.
The company is owned by Ampio Pharmaceuticals (NYSEMKT: AMPE). A female sexual dysfunction biotech, S1 Biopharma ([SXB]), had set terms to raise $36 million earlier this month but postponed its offering.
The Greenwood Village, CO-based company was founded in 2013. VYRX. Aegis Capital and Fordham Financial Management were set to be the joint ...more
Polar Star Realty Trust, a REIT formed to own office and industrial property in Norway and Sweden, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $500 million by offering 43.5 million shares at a price range of $10 to $13. At the midpoint of the proposed range, Polar Star Realty Trust would command a fully diluted market value of $800 million.
The year's two largest REIT IPOs, Paramount Group ([PGRE]) and STORE Capital ([STOR]), priced last week and trade up 5% and 7% respectively.
Polar Star Realty Trust, which was founded in 1999 and ...more
11/21/14 Analyst IPO Blog
9 companies went public in the past week as the IPO market raised $3.5 billion. At 26 deals, November issuance fell one IPO short of last year, unless CVSL manages to price next week. November IPOs raised $7.2 billion and averaged 19% from the offer price, including 4% after the first day. Two companies rose over 100% on their debut, the sixth and seventh IPOs of 2014 to do so.
Retinal implant maker Second Sight Medical Products spiked 122% on its first day and fast casual burger chain The Habit ...more